作者
Julio Chirinos, Patricio Lopez-Jaramillo, Evangelos Giamarellos-Bourboulis, Gonzalo Dávila-del-Carpio, Abdul Bizri, Jaime Andrade-Villanueva, Oday Salman, Carlos Cure-Cure, Nelson Rosado-Santander, Mario Cornejo Giraldo, Luz González-Hernández, Rima Moghnieh, Rapti Angeliki, María Cruz Saldarriaga, Marcos Pariona, Carola Medina, Ioannis Dimitroulis, Charalambos Vlachopoulos, Corina Gutierrez, Juan Rodriguez-Mori, Edgar Gomez-Laiton, Rosa Pereyra, Jorge Ravelo Hernández, Hugo Arbañil, José Accini-Mendoza, Maritza Pérez-Mayorga, Haralampos Milionis, Garyfallia Poulakou, Gregorio Sánchez, Renzo Valdivia-Vega, Mirko Villavicencio-Carranza, Ricardo Ayala-Garcia, Carlos Castro-Callirgos, Rosa Alfaro Carrasco, Willy Lecca Danos, Tiffany Sharkoski, Katherine Greene, Bianca Pourmussa, Candy Greczylo, Jesse Chittams, Paraskevi Katsaounou, Zoi Alexiou, Styliani Sympardi, Nancy Sweitzer, Mary Putt, Jordana Cohen
发表日期
2022/8/10
期刊
Research Square
出版商
American Journal Experts
简介
Background
Abnormal cellular lipid metabolism appears to underlie SARS-CoV-2 cytotoxicity and may involve inhibition of peroxisome proliferator activated receptor alpha (PPARα). Fenofibrate, a PPAR-α activator, modulates cellular lipid metabolism. Fenofibric acid has also been shown to affect the dimerization of angiotensin-converting enzyme 2, the cellular receptor for SARS-CoV-2. Fenofibrate and fenofibric acid have been shown to inhibit SARS-CoV-2 replication in cell culture systems in vitro.
Methods
We randomly assigned 701 participants with COVID-19 within 14 days of symptom onset to 145 mg of fenofibrate (nanocrystal formulation with dose adjustment for renal function or dose-equivalent preparations of micronized fenofibrate or fenofibric acid) vs. placebo for 10 days, in a double-blinded fashion. The primary endpoint was a ranked severity score in which participants were ranked across hierarchical …
学术搜索中的文章
J Chirinos, P Lopez-Jaramillo… - Research Square, 2022